• Subscribe
  • About us
  • Advertise with us

NeuroSens

Menu

Skip to content
  • Home
  • Neurology
  • Psychiatry

Topic: MS

Assessing the nocebo effect in MS trials

January 5, 2010  

Pulsed methylprednisolone: MECOMBIN trial results

January 5, 2010  

Teriflunomide in combination with beta-IFN: preliminary results

January 5, 2010  

Cognitive impairment in adolescent MS: follow-up results

December 15, 2009  

Alemtuzumab in MS: 4-year follow-up

December 15, 2009  

Vitamin D in MS: update on new studies

December 15, 2009  

EBV: an association with MS?

November 3, 2009  

Smoking may increase risk of MS disease progression

October 20, 2009  

Viral reactivation with natalizumab

October 6, 2009  

Predictors of response: results from long-term follow-up

July 21, 2009  
Previous
40
41
42
43
44
Next

Browse by Topic

  • MS (442)
  • EAN 2026 (2)
  • CLINICAL CASES (21)
  • AAN 2026 (3)
  • ACTRIMS Forum 2026 (4)
  • EPILEPSY (38)
  • AES 2025 (1)
  • BIOMARKERS IN MS (61)
  • ECTRIMS 2025 (7)
  • Library (18)
  • EAN 2025 (2)
  • AAN 2025 (5)
  • ACTRIMS 2025 (6)
  • AES 2024 (1)
  • ECTRIMS 2024 (6)
  • EAN 2024 (3)
  • AD (85)
  • AAN 2024 (5)
  • ACTRIMS Forum 2024 (2)
  • PD (77)
  • COVID-19 (58)
  • MIGRAINE (25)
  • DEPRESSION (36)
  • STROKE (22)
  • SCHIZOPHRENIA (25)
  • DEMENTIA (10)
  • SLEEP (2)
  • PAIN (3)
  • BPD (4)
  • ALS (1)

Popular Posts

  • Anti-CD20 therapy in MS: comparing efficacy and safety posted on July 21, 2026
  • Highlights of EAN 2026 – Part 1 posted on June 30, 2026
  • Proton pump inhibitors linked to neurological conditions posted on November 29, 2019
Copyright 2026 Lind Publishing Inc All rights reserved. Developed by Integration New Media, INC. (INM)
Contact Us Terms and Conditions